WE CLAIM:

5

15

- 1. A composition comprising one or more pharmaceutical agents selected from the group consisting of an α -adrenergic blocker, a phosphodiesterase inhibitor, and a prostaglandin in a buffer wherein said buffer comprises a substrate for nitric acid synthetase.
- 2. The composition of claim 1 wherein the α -adrenergic blocker is phentolamine mesylate, or any pharmaceutically acceptable salt thereof.
- 3. The composition of claim 1 wherein the phosphodiesterase inhibitor is selected from the group consisting of papaverine hydrochloride or Sildenafil or any pharmaceutically acceptable salt thereof.
 - 4. The composition of claim 1 wherein the prostaglandin is alprostadil.
 - 5. The composition of claim 1 wherein the buffer comprises L-arginine and, optionally, a pharmaceutically acceptable excipient or carrier.
 - 6. The composition of claim 5 wherein the buffer comprises glycine having a pH range of from about 3 to about 5.
 - 7. The composition of claim 1 wherein the buffer comprises a mixture of arginine and glycine having a pH range of from about 3 to about 5.
 - 8. The composition of claim 1 wherein the buffer comprises glycine and L-arginine in a weight ratio of about 1:20.

- The composition of claim 7 wherein the buffer further 9. comprises benzyl alcohol and mannitol and has a pH range of from about 3 to about 5.
- The composition of claim 1 wherein the weight ratio of 10. phentolamine mesylate: papaverine hydrochloride: alprostadil is about 0.5:7.5:0.005 to about 5:30:0.02.
- The composition of claim 1 wherein the weight ratio of 11. phentolamine mesylate: papaverine hydrochloride: alprostadil is about 1:30:0.01.

12. The composition of claim 1 wherein the dosage of 10 phentolamine mesylate, papaverine hydrochloride, and alprostadil are in the range of about 0-40 µg/ml alprostadil, about 0-50 mg/ml papaverine, and

about 0-10 mg/ml phentolamine.

- The composition of claim 1 wherein the dosage of 13. phentolamine mesylate, papaverine hydrochloride, and alprostadil are in the range of about 1.25-5 mg/ml phentolamine, about 7.5-30 mg/ml papaverine, and about 5-20 µg/ml alprostadil.
- 14. The composition of claim 1 wherein the dosage of phentolamine mesylate, papaverine hydrochloride, and alprostadil are about 1 mg/ml phentolamine, about 30 mg/ml papaverine, and about 0.01 mg/ml alprostadil.
- The composition of claims 12, 13, or 14 wherein the 15. vasoactive agents are present in a total volume of 0.5 µl.
- The composition of claim 1 wherein the dosage of 16. alprostadil is about 5 µg/ml in a total volume of 0.5 ml.

5

15

20

- 17. The composition of claim 1 wherein the dosage of phentolamine is about 1.25 mg/ml in a total volume of 0.5 ml.
- 18. The composition of claim 1 wherein the pH range of the buffer is from about 3 to about 7.

19. A method for the treatment of male erectile dysfunction which comprises administering a pharmacologically effective amount of a composition comprising one or more of the following pharmaceutical agents selected from the group consisting of an α -adrenergic blocker, a phosphodiesterase inhibitor, and a prostaglandin in a buffer.

5

10

15

20

20. The method of claim 19 wherein the α -adrenergic blocker is phentolamine mesylate, or any pharmaceutically acceptable salt thereof.

- 21. The method of claim 19 wherein the phosphodiesterase inhibitor is papaverine hydrochloride or any pharmaceutically acceptable salt thereof.
- 22. The method of claim 19 wherein the prostaglandin is alprostadil.
- 23. The method of claim 19 wherein the buffer comprises Larginine and, optionally, a pharmaceutically acceptable excipient or carrier.
- 24. The method of claim 23 wherein the buffer comprises glycine having a pH range of from about 3 to about 5.
- 25. The method of claim 19 wherein the buffer comprises a mixture of arginine and glycine having a pH range of from about 3 to about 5.

- 26. The method of claim 19 wherein the buffer comprises glycine and L-arginine in a weight ratio of about 1:20.
- 27. The method of claim 25 wherein the buffer further comprises benzyl alcohol and mannitol and has a pH range of from about 3 to about 5.
- 28. The method of claim 19 wherein the weight ratio of phentolamine mesylate: papaverine hydrochloride: alprostadil is about 0.5:7.5:0.005 to about 5:30:0.02.

5

10

15

20

- 29. The method of claim 19 wherein the weight ratio of phentolamine mesylate: papaverine hydrochloride: alprostadil is about 1:30:0.01.
 - 30. The method of claim 19 wherein the dosage of phentolamine mesylate, papaverine hydrochloride, and alprostadil are in the range of about 0-40 µg/ml alprostadil, about 0-50 mg/ml papaverine, and about 0-10 mg/ml phentolamine.
 - 31. The method of claim 19 wherein the dosage of phentolamine mesylate, papaverine hydrochloride, and alprostadil are in the range of about 1.25-5 mg/ml phentolamine, about 7.5-30 mg/ml papaverine, and about 5-20 µg/ml alprostadil.
 - 32. The method of claim 19 wherein the dosage of phentolamine mesylate, papaverine hydrochloride, and alprostadil are about 1 mg/ml phentolamine, about 30 mg/ml papaverine, and about 0.01 mg/ml alprostadil.
 - 33. The method of claim 30, 31, or 32 wherein the vasoactive agents are present in a total volume of 0.5 µl.

- 34. The method of claim 19 wherein the dosage of alprostadil is about 5 μ g/ml in a total volume of 0.5 ml.
- 35. The method of claim 19 wherein the dosage of phentolamine is about 1.25 mg/ml in a total volume of 0.5 ml.

5

10

15

- 36. The method of claim 19 wherein the pH range of the buffer is from about 3 to about 7.
- 37. A composition comprising an α -adrenergic blocking agent, a phosphodiesterase inhibitor and a prostaglandin in a pharmaceutically acceptable carrier or excipient.
- 38. The composition of claim 37 wherein the α -adrenergic blocking agent is phentolamine or a pharmaceutically acceptable salt thereof.
 - 39. The composition of claim 37 wherein the phosphodiesterase inhibitor is selected from the group consisting of Sildenafil and papaverine or pharmaceutically acceptable salts thereof.
- 40. The composition of claim 37 wherein the prostaglandin is alprostidil.
- 41. The composition according to claim 37, 38, 39, and 40 further comprising a buffer.
- 42. The composition according to claim 41 wherein the buffer comprises glycine, arginine, or a mixture thereof.
 - 43. The composition according to claim 41 wherein the composition has a pH range from about 3 to about 7.

- 44. The composition according to claim 41 wherein the composition has a pH range from about 3 to about 5.
- 45. The composition according to claim 42 wherein the composition has a pH range from about 3 to about 7.
- 46. The composition according to claim 42 wherein the composition has a pH range from about 3 to about 5.